Now on
Collaboration agreement between Telethon Foundation and Rare Partners
Collaboration agreement between Telethon Foundation and Rare Partners
The European Commission grants Orphan Drug Designation to 4,6,4’–trimethylangelicin for the treatment of Cystic Fibrosis
The European Commission grants Orphan Drug Designation to 4,6,4’–trimethylangelicin for the treatment of Cystic Fibrosis
Thanks to all Rare Runners who have run with us and for us
Thanks to all Rare Runners who have run with us and for us
Rare Partners presents a poster on Rapamycin project
Rare Partners announces the presentation of a poster at the ECRD meeting 2012
Rare Partners announces a three parties alliance for thalassemia
Rare Partners announces a three parties alliance for the use of rapamycin in thalassemic patients, based on the research carried out by Professor Roberto Gambari and coworkers at the University of Ferrara.